PharmChem, Inc. (PCHM)
USD 3.0
(-0.13%)
USD 3.0
(-0.13%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.05 Million USD | -10.03% |
| 2022 | 1.1 Million USD | -29.96% |
| 2021 | 1.67 Million USD | -27.92% |
| 2020 | 2.16 Million USD | 30.82% |
| 2019 | 1.73 Million USD | 11.86% |
| 2018 | 1.47 Million USD | 18.1% |
| 2017 | 1.24 Million USD | 19.41% |
| 2016 | 1.04 Million USD | 0.0% |
| 2002 | 1.46 Million USD | 109.17% |
| 2001 | -4.07 Million USD | -199.13% |
| 2000 | 4.11 Million USD | -4.3% |
| 1999 | 4.3 Million USD | 63.5% |
| 1998 | 3.21 Million USD | 145.79% |
| 1997 | 1.07 Million USD | -55.36% |
| 1996 | 2.39 Million USD | -79.69% |
| 1995 | 3.1 Million USD | 321.43% |
| 1994 | 2.8 Million USD | -44.0% |
| 1993 | 1.6 Million USD | 4.17% |
| 1992 | 4.8 Million USD | -14.29% |
| 1991 | 4.9 Million USD | 96.0% |
| 1990 | 2.5 Million USD | 525.0% |
| 1989 | 400 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 193.14 Thousand USD | -33.85% |
| 2024 Q2 | 657.34 Thousand USD | 222.25% |
| 2023 Q1 | 158.5 Thousand USD | -31.95% |
| 2023 FY | - USD | -10.03% |
| 2023 Q4 | 297.19 Thousand USD | 5.4% |
| 2023 Q2 | 213.4 Thousand USD | 34.64% |
| 2023 Q3 | 281.96 Thousand USD | 32.13% |
| 2022 Q3 | 285.3 Thousand USD | 44.47% |
| 2022 Q1 | 342.08 Thousand USD | -23.21% |
| 2022 Q2 | 197.48 Thousand USD | -42.27% |
| 2022 FY | - USD | -29.96% |
| 2022 Q4 | 232.93 Thousand USD | -18.36% |
| 2021 FY | - USD | -27.92% |
| 2021 Q3 | 120 Thousand USD | -72.86% |
| 2021 Q2 | 442.09 Thousand USD | -17.69% |
| 2021 Q4 | 445.45 Thousand USD | 271.21% |
| 2021 Q1 | 537.11 Thousand USD | 0.0% |
| 2020 FY | - USD | 30.82% |
| 2019 FY | - USD | 11.86% |
| 2018 FY | - USD | 18.1% |
| 2017 FY | - USD | 19.41% |
| 2016 FY | - USD | 0.0% |
| 2003 Q1 | -28 Thousand USD | 83.07% |
| 2003 Q3 | 165 Thousand USD | 42.48% |
| 2003 Q2 | 116 Thousand USD | 362.79% |
| 2002 Q3 | -90 Thousand USD | -124.15% |
| 2002 Q2 | 465 Thousand USD | 1.74% |
| 2002 Q4 | -254 Thousand USD | -156.57% |
| 2002 FY | - USD | 109.17% |
| 2002 Q1 | 335 Thousand USD | 197.34% |
| 2001 FY | - USD | -199.13% |
| 2001 Q3 | -917 Thousand USD | 66.44% |
| 2001 Q2 | -4.8 Million USD | -34475.0% |
| 2001 Q1 | -402 Thousand USD | -98.92% |
| 2001 Q4 | 419 Thousand USD | 55.15% |
| 2000 Q4 | 1.21 Million USD | -39.28% |
| 2000 Q3 | 1.22 Million USD | 10.79% |
| 2000 FY | - USD | -4.3% |
| 2000 Q2 | 1.1 Million USD | 5.25% |
| 2000 Q1 | 1.04 Million USD | -73.87% |
| 1999 Q3 | 1.8 Million USD | 80.0% |
| 1999 FY | - USD | 63.5% |
| 1999 Q2 | 1 Million USD | 11.11% |
| 1999 Q1 | 900 Thousand USD | -76.97% |
| 1999 Q4 | 4.01 Million USD | 122.83% |
| 1998 FY | - USD | 145.79% |
| 1998 Q1 | 500 Thousand USD | -85.59% |
| 1998 Q2 | 1 Million USD | 100.0% |
| 1998 Q3 | 1 Million USD | 0.0% |
| 1998 Q4 | 3.9 Million USD | 290.8% |
| 1997 Q4 | 3.47 Million USD | 3570.0% |
| 1997 Q1 | 200 Thousand USD | -94.28% |
| 1997 FY | - USD | -55.36% |
| 1997 Q2 | 400 Thousand USD | 100.0% |
| 1997 Q3 | -100 Thousand USD | -125.0% |
| 1996 Q3 | 700 Thousand USD | -22.22% |
| 1996 Q4 | 3.49 Million USD | 399.57% |
| 1996 Q1 | 200 Thousand USD | -97.67% |
| 1996 FY | - USD | -79.69% |
| 1996 Q2 | 900 Thousand USD | 350.0% |
| 1995 Q4 | 200 Thousand USD | 681.82% |
| 1995 Q1 | 900 Thousand USD | 50.0% |
| 1995 Q2 | 9.7 Million USD | 977.78% |
| 1995 Q3 | 1.1 Million USD | -88.66% |
| 1995 FY | - USD | 321.43% |
| 1994 Q3 | 900 Thousand USD | -89.29% |
| 1994 Q4 | 600 Thousand USD | -33.33% |
| 1994 Q2 | 8.4 Million USD | 1580.0% |
| 1994 Q1 | 500 Thousand USD | 183.33% |
| 1994 FY | - USD | -44.0% |
| 1993 Q1 | 7.4 Million USD | 144.58% |
| 1993 Q2 | 1.1 Million USD | -85.14% |
| 1993 Q3 | 200 Thousand USD | 245.45% |
| 1993 Q4 | -600 Thousand USD | -115.79% |
| 1993 FY | - USD | 4.17% |
| 1992 Q3 | 6.8 Million USD | -5.56% |
| 1992 Q1 | 6.3 Million USD | 145.99% |
| 1992 Q2 | 7.2 Million USD | 14.29% |
| 1992 FY | - USD | -14.29% |
| 1992 Q4 | -16.6 Million USD | -344.12% |
| 1991 FY | - USD | 86.67% |
| 1991 Q1 | 4.3 Million USD | 142.57% |
| 1991 Q2 | 6.6 Million USD | 53.49% |
| 1991 Q3 | 6.5 Million USD | -1.52% |
| 1991 Q4 | -13.7 Million USD | -310.77% |
| 1990 Q3 | 3.9 Million USD | 0.0% |
| 1990 Q4 | -10.1 Million USD | -358.97% |
| 1990 Q2 | 3.9 Million USD | 2.63% |
| 1990 Q1 | 3.8 Million USD | 148.1% |
| 1990 FY | - USD | 233.33% |
| 1989 Q1 | 2.5 Million USD | 0.0% |
| 1989 Q3 | 2.6 Million USD | 0.0% |
| 1989 Q4 | -7.9 Million USD | -403.85% |
| 1989 FY | - USD | 0.0% |
| 1989 Q2 | 2.6 Million USD | 4.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 190.611% |
| Arrayit Corporation | -3.07 Million USD | 134.242% |
| Atlantic International Corp. | -5.38 Million USD | 119.553% |
| Biocept, Inc. | -30.24 Million USD | 103.485% |
| Bioqual, Inc. | 3.03 Million USD | 65.246% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 239.14% |
| DermTech, Inc. | -97.89 Million USD | 101.076% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 99.964% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 105.206% |
| iMD Companies, Inc. | -154.65 Thousand USD | 781.376% |
| IDenta Corp. | 71.58 Thousand USD | -1372.069% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 72.536% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -2623.727% |
| InVitro International | 6680.00 USD | -15675.599% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 119.386% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 8784.77% |
| Medical Imaging Corp. | -896.74 Thousand USD | 217.515% |
| NovelStem International Corp. | -3.78 Million USD | 127.836% |
| Optigenex Inc. | -1.18 Million USD | 188.8% |
| Proteome Sciences plc | -1.13 Million USD | 192.683% |
| Response Genetics, Inc | -19.66 Million USD | 105.359% |
| Rennova Health, Inc. | -234.81 Thousand USD | 548.783% |
| RushNet, Inc. | -614.85 Thousand USD | 271.392% |
| ScreenPro Security Inc. | -3.43 Million USD | 130.68% |
| Stella Diagnostics Inc. | -5.7 Million USD | 118.464% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 110.261% |
| Todos Medical Ltd. | -9.39 Million USD | 111.218% |